Actelion retained at neutral

Merrill Lynch analyst Erica Whittaker retained Actelion Ltd. at neutral while increasing sales and profitability forecasts due to reported second-quarter global volume growth of Tracleer globally and a U.S. price increase. The theoretical fair value for Actelion was increased to CHF 142 per share from CHF 134. Shares of the Allschwil, Switzerland-based pharmaceutical company were up CHF 1.30, or 0.95%, at CHF 138.70 on volume of 451,281 shares versus the three-month running average of 159,397 shares. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.